Immune Checkpoints

• 2796 · PDF Translating combined PD1 and LAG3 inhibition from preclinical models to patients with refractory, DNA replication repair deficient (RRD) glioblastoma: An IRRDC study Anirban Das, Vienna Mazzoli, Owen Crump, Olha Kos, Nuno M. Nunes, Lucie Stengs, Amanda Li, Adrian Levine, Yoshiko Nakano, Hope Friedman, Katharine O'Flaherty, Alexander Stein, Gadi Abebe-Campino, Annika Bronsema, Vanessa Bianchi, Melissa Edwards, Stergios Zacharoulis, Birgit Ertl-Wagner, Daniel A. Morgenstern, Trevor J. Pugh, Pamela Ohashi, Eric Bouffet, Cynthia E. Hawkins, Peter B. Dirks, Uri Y. Tabori
• 2797 · PDF A macrophage endocytic checkpoint for PD-1 governs durable vs hyperprogressive response Madhubanti Mullick, Ella McLaren, Suchismita Roy, Brandon Biagas, Mahitha Anandachar, Vanessa Castillo, Samuel Williams, Celia Espinoza, Courtney Tindle, Gajanan Katkar, Saptarshi Sinha, Pradipta Ghosh
• 2798 · PDF CD112 drives tumor immune evasion in HER2-positive breast cancer through sphingolipid metabolism-dependent remodeling of CD8+T cell receptor landscapeand consequent dysfunction YI ZHANG, Bingqiu Xiu, Jiong Wu, Qi Zhang
• 2799 · PDF Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation Alyssa Mauri Cornista, Tao Yu, Zhuolong Zhou, Nikša Roki, Alberto Sigler, David M. Suissa, Haniyeh Eyvani, George E. Sandusky, Rimpi Khurana, Yan Guo, Molly Dalzell, Shyamananda Singh Mayengbam, Prasenjit Dey, Christine Rafie, Erietta Stelekati, Jashodeep Datta, Saratchandra S. Khumukcham, Jatin Roper, Nivedh Paluvoi, Sandro Satta, Daniel Bilbao Cortes, Alejandro Villarino, Kevin Van der Jeught
• 2800 · PDF Understanding the mechanism by which CD4 + T cells sensitize mesenchymal CD73-deficient tumors to anti-CTLA4 immune checkpoint blockade therapy Brian Hongtao Feng, Caitie Hanna Sams, Isabel O'Connell, Shiney Chandraganti, Anushka Dongre
• 2801 · PDF SRY-mediated upregulation of PD-L1 promotes immune evasion in hepatocellular carcinoma and contributes to sex-specific disparities in immunotherapy response Bingyi Ren, Kai Sheng, Yichen Yang
• 2802 · PDF In vitro antigen-specific T cell exhaustion model for immunomodulators evaluation Emilio Cosimo, Hannah Findlay, Robert Benson, Agapitos Patakas
• 2803 · PDF Ex vivo micro-tumor testing platform to characterize and predict patient-specific immunotherapy drug responses Felix M. Behr, Esmee Koedoot, Timothy J. P. Sijsenaar, Léa Le Large, Cor D. de Kroon, Anne van Altena, Farbod Khoraminia, Laurie C. Steinbusch, Christi M. Steendam, Dieudonné J. van der Meer, Willemijn Vader, Nelleke Ottevanger, Judith R. Kroep
• 2804 · PDF Sialic acid inhibits engager-mediated T cell activation Johanna Nimmerfroh, Dinah Heiligensetzer, Michael Sandholzer, Anastasiya Börsch, Heinz Laubli
• 2806 · PDF Myoglobin expression boosts T-cell metabolism and antitumor effector function Julia Werner, Haifeng Xu, Georgios Theodorakis, Ichiro Katahira, Mitrajit Ghosh, Michal Gorzkiewicz, Luisa de Sousa Santos, Ann Kathrin Bergmann, Max Anstötz, Anne Busch, Diran Herebian, Sascha Dietrich, Carsten Berndt, Ertan Mayatepek, Aleksandra Pandyra, Dirk Brenner, Philipp Lang
• 2807 Immune cell-dependent resistance to LAG3 blockade in SMARCB1-deficient renal medullary carcinoma Jing Qian, Kai Yu, Deepa Bisht, Melinda Soeung, Pankaj Chauhan, Fei Duan, Menuka Karki, Rong He, Nizar M. Tanir, Hania Khan, Zilong Zhao, Luigi Perelli, Giannicola Genovese, Linghua Wang, Jianjun Gao, Pavlos Msaouel
• 2808 · PDF A first in class VIP receptor antagonist as an immunotherapeutic for acute myeloid leukemia Swapnaa Balaji, Antonio Ward, Yuou Wang, Jian-Ming Li, Srijon Sarkar, Sonia Mecorapaj, Tenzin Kalsang, Shuhua Wang, Cynthia Giver, Edmund Waller
• 2809 · PDF VIP/VPAC signaling as a phagocytosis checkpoint in TP53-mutated acute myeloid leukemia Zihan (Clarence) Chen, Tuisha Gupta, Fanyuan Zeng, Yujie Chen, Jian Ming Li, Cynthia R. Giver, Kiranj Chaudagar, Edmund K. Waller
• 2810 · PDF Anti-PD-1 efficacy is associated with a clonal trajectory composed of chronic effectors with lymph node homing capacity Mingshuang Wang*, Guanning Wang*, Khushboo Patel, Ajeya Nandi, Timmy Lai, Shira Rosenberg, Zhoumu Xiang, Stella Park, Tara C. Mitchell, Alexander C. Huang#
• 2812 · PDF Bhlhe40 shapes distinct T cell reponses to anti PD1 and anti CTLA4 immune checkpoint therapy Akata Saha, Tomoyuki Minowa, Alexander S. Shavkunov, Avery J. Salmon, Sunita Keshari, Kristen E. Pauken, Kenneth H. Hu, Ken Chen, Matthew M. Gubin
• 2813 · PDF Targeting AHR overcomes PD-L1-driven resistance to immune checkpoint blockade in triple-negative breast cancer Minkyoung Choi, Ju Hee Kim, Han-Byoel Lee, Wonshik Han
• 2814 · PDF Comprehensive single-cell atlas of immune ecosystem in response to immune checkpoint blockade therapy Dayoung Lee, Ji Yoon Lee, Jiwon Kim, You Jin Song, Namsung Moon, Juyoung Lee, Harim Koo, Jason K. Sa
• 2815 · PDF Cytoplasmic PD-L1 levels are associated with tumor progression in small cell lung cancer Ji Young Lee, Anindita Das, HyeonJoo Cheon
• 2816 · PDF Discovery and preclinical evaluation of novel peptide inhibitors targeting the TIGIT immune checkpoint Haozhe Cui, Xinyi Zhang, Wanding Wang, Francesco Zonta, Eyad Elkord
• 2817 · PDF Immune checkpoint therapy induces tertiary lymphoid structures in a murine model of triple-negative breast cancer Zachary D. Schrank, Benjamin G. Vincent, Jonathan S. Serody
• 2818 · PDF Preclinical Characterization of ALG-094295, a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting dimerization, internalization and degradation of PD-L1 Heleen Roose, Kristina Rekstyte-Matiene, Sarah Stevens, Kusum Gupta, Sandra Chang, Nour Fayyad, Cheng Liu, Vladimir Serebryany, Lillian Adame, Kha Le, Antitsa Stoycheva, Dinah Misner, Lawrence M. Blatt, Sushmita Chanda, David B. Smith, Julian A. Symons, Andreas Jekle, Tongfei Wu
• 2819 · PDF Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting PD-L1 dimerization, internalization and degradation Heleen Roose, Kristina Rekstyte-Matien, Sarah Stevens, Kusum Gupta, Sandra Chang, Nour Fayyad, Cheng Liu, Vladimir Serebryany, Lillian Adame, Kha Le, Antitsa Stoycheva, Dinah Misner, Lawrence M. Blatt, Leonid Beigelman, Sushmita Chanda, David B. Smith, Julian A. Symons, Andreas Jekle, Tongfei Wu
• 2820 · PDF Spatial mapping of PD1-PD-L2 interactions suggests an additional checkpoint axis in non-small cell lung cancer Anna Gorbunova, Amanda Lindberg, Lars Muhl, Ghazal Lessan Toussi, Hui Yu, Patrick Micke, Carina Strell
• 2821 · PDF TRIB2 regulates immune evasion in antiandrogen-resistant and neuroendocrine prostate cancer Sharad K. Suthar, Azizur Rahman, Sang-Yoon Lee, Jitender Monga
• 2822 · PDF Serial transcriptomic analyses capture the effects of neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer Blair V. Landon, Christopher Cherry, Rachel Keogh, Jaime Wehr, Gavin Pereira, Noushin Niknafs, Richard J. Battafarano, Stephen C. Yang, Stephen Broderick, Jinny Ha, Russell K. Hales, K. Ranh Voong, Kristen A. Marrone, Chen Hu, Josephine L. Feliciano, Ali H. Zaidi, Ronan J. Kelly, Vincent K. Lam, Valsamo (Elsa) K. Anagnostou
• 2823 · PDF Single-cell RNA-seq reveals insights into the effects of immune checkpoint inhibitors Junting Lu, Jinghui Xiu, Ce Zhong, Wentao Li, Wei Yun, Tan Pang, Jingqi Huang
• 2824 Intragenic rearrangement burden: A novel biomarker to predict immune checkpoint blockade response in TMB-low cancers Akshat Gupta, Selena Xiao, Hillary Wang, Rohit Bhargava, Adrian V. Lee, Adam M. Brufsky, Xiaosong Wang

在完整检索应用中浏览本分会场 →